Sorafenib increases 18-FDG colic uptake: demonstration in patients with differentiated thyroid cancer

BACKGROUND: To assess 18-fluorodeoxyglucose (FDG) bowel uptake in patients with differentiated thyroid cancer (DTC) treated with sorafenib. FINDINGS: Visual (5-point scale) and high maximum standard uptake value (SUVmax) semi-quantitative analyses were conducted in 63 positron emission tomography (P...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciappuccini, Renaud, Trzepla, Géraldine, Heutte, Natacha, Sevin, Emmanuel, Galais, Marie Pierre, Bardet, Stéphane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2012
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3426461/
https://www.ncbi.nlm.nih.gov/pubmed/22564710
http://dx.doi.org/10.1186/2191-219X-2-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3426461/
https://www.ncbi.nlm.nih.gov/pubmed/22564710
http://dx.doi.org/10.1186/2191-219X-2-18

Ejemplares similares